Last reviewed · How we verify
BOSUTINIB MONOHYDRATE
At a glance
| Generic name | BOSUTINIB MONOHYDRATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2012 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia (PHASE2)
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BOSUTINIB MONOHYDRATE CI brief — competitive landscape report
- BOSUTINIB MONOHYDRATE updates RSS · CI watch RSS